Peter Speirs - Hikma Pharmaceuticals Company Secretary
HKMPY Stock | USD 46.50 0.00 0.00% |
Executive
Mr. Peter Speirs is Company Secretary of Hikma Pharmaceuticals Plc. Peter is responsible for advising on governance, executive remuneration, and listing related matters. Peter joined Hikma as Deputy Secretary and previously held roles with Barclays and Pool Re. since 2012.
Tenure | 12 years |
Phone | 44 20 7399 2760 |
Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Kathleen Fitzpatrick | Bausch Health Companies | N/A | |
Berrin Noorata | Tilray Inc | N/A | |
Seana Carson | Bausch Health Companies | 51 | |
John MBA | Catalent | 69 | |
Mitchell Gendel | Tilray Inc | 58 | |
Paul Surdez | Catalent | N/A | |
Josh Coyle | Bausch Health Companies | N/A | |
Arthur Shannon | Bausch Health Companies | N/A | |
Roger Savell | Tilray Inc | 62 | |
Edward Pastorius | Tilray Inc | 49 | |
John Sadler | Tilray Inc | N/A | |
Lisa Evoli | Catalent | 54 | |
Theodora Mistras | Viatris | N/A | |
Jiny MBA | Bausch Health Companies | 47 | |
Andrew Pucher | Tilray Inc | N/A | |
Donald Pearl | Bausch Health Companies | N/A | |
Cees Heiman | Bausch Health Companies | N/A | |
Paul Campbell | Viatris | 56 | |
Randy Daigneau | Tilray Inc | N/A | |
Andrew Enrietti | Viatris | N/A | |
Ramkumar Rayapureddy | Viatris | N/A |
Management Performance
Return On Equity | 0.15 | |||
Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
Khalid Nabilsi, Chief Officer | ||
Hussein Arkhagha, General Counsel | ||
Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
Pamela Kirby, Non-Executive Independent Director | ||
John Castellani, Non-Executive Independent Director | ||
Brian Hoffman, President and Chief Executive of - Generics Division | ||
Ali AlHusry, Non-Executive Director | ||
Jochen Gann, Non-Executive Director | ||
Engineer Darwazah, Ex CEO | ||
Peter Speirs, Company Secretary | ||
Patrick Butler, Non-Executive Independent Director | ||
Brian Hoffmann, Pres Generics | ||
Said Darwazah, Chairman and CEO | ||
Michael Raya, President and CEO, USA | ||
Samuel Park, Global US | ||
Ronald Goode, Non-Executive Independent Director | ||
Bryan Hotston, CIO | ||
Sigurdur Olafsson, CEO | ||
Breffni Byrne, Non-Executive Independent Director | ||
Nina Henderson, Non-Executive Independent Director | ||
Cynthia Schwalm, Independent Non-Executive Director | ||
Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
Michael Ashton, Non-Executive Independent Director | ||
Majda Labadi, Corporate Vice President - Human Resources | ||
Ibrahim Jalal, Sr. Corporate VP of Technical Affairs | ||
Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
Robert Pickering, Senior Non-Executive Independent Director | ||
Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
CPA CFA, Exec MA |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.15 | |||
Return On Asset | 0.077 | |||
Profit Margin | 0.14 % | |||
Operating Margin | 0.22 % | |||
Current Valuation | 5.26 B | |||
Shares Outstanding | 110.13 M | |||
Price To Earning | 10.10 X | |||
Price To Book | 1.89 X | |||
Price To Sales | 1.60 X | |||
Revenue | 2.55 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hikma Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hikma Pharmaceuticals' short interest history, or implied volatility extrapolated from Hikma Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |